产品封面图
文献支持

PANC05.04细胞

收藏
  • ¥1320
  • BHcell(博辉生物)
  • BH-C165
  • 2026年01月16日
    avatar
  • 企业认证

    点击 QQ 联系

  • 万千商家帮你免费找货

    0 人在求购买到急需产品
    • 详细信息
    • 文献和实验
    • 技术资料
    • 规格

      T25

    PANC 05.04 /PANC 05.04 细胞系/PANC 05.04 细胞株/PANC 05.04 人胰腺癌细胞

    Cell line name Panc 05.04

    Synonyms Panc-05.04; Panc_05_04; Panc05.04; Panc 5.04; Panc5.04; PANC0504; Panc0504; Pa18C; PL-18; PL18

    Accession CVCL_1637

    Secondary accession CVCL_X507

    Resource Identification Initiative To cite this cell line use: Panc 05.04 (RRID:CVCL_1637)

    Comments Problematic cell line: Partially contaminated. Some stocks of this cell line such as the one used by Sanger cell line project were contaminated with a OCUG-1 derivative as shown by STR profile and SNP fingerprinting analysis (DepMap).

    Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

    Part of: COSMIC cell lines project.

    Part of: MD Anderson Cell Lines Project.

    Part of: TCGA-110-CL cell line panel.

    From: Johns Hopkins University School of Medicine; Baltimore; USA.

    Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00614.

    Population: Caucasian.

    Doubling time: 46.0 hours (PubMed=9612602).

    Omics: Deep exome analysis.

    Omics: Deep proteome analysis.

    Omics: Metabolome analysis.

    Omics: Protein expression by reverse-phase protein arrays.

    Omics: SNP array analysis.

    Omics: Transcriptome analysis by microarray.

    Omics: Transcriptome analysis by RNAseq.

    Derived from site: In situ; Pancreas; UBERON=UBERON_0001264.

    PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

    Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

    The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

    Nature 483:603-607(2012)

     

    PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224; PMCID=PMC5057396

    Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.-Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J.

    Essential gene profiles in breast, pancreatic, and ovarian cancer cells.

    Cancer Discov. 2:172-189(2012)

     

    PubMed=22753594; DOI=10.1158/1078-0432.CCR-12-0827; PMCID=PMC3513499

    Cui Y.-F., Brosnan-Cashman J.A., Blackford A.L., Sur S., Hruban R.H., Kinzler K.W., Vogelstein B., Maitra A., Diaz L.A. Jr., Iacobuzio-Donahue C.A., Eshleman J.R.

    Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity.

    Clin. Cancer Res. 18:6519-6530(2012)

     

    PubMed=25167228; DOI=10.1038/bjc.2014.475; PMCID=PMC4453732

    Hamidi H., Lu M., Chau K., Anderson L., Fejzo M.S., Ginther C., Linnartz R., Zubel A., Slamon D.J., Finn R.S.

    KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.

    Br. J. Cancer 111:1788-1801(2014)

     

    PubMed=25485619; DOI=10.1038/nbt.3080

    Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

    A comprehensive transcriptional portrait of human cancer cell lines.

    Nat. Biotechnol. 33:306-312(2015)

     

    PubMed=25877200; DOI=10.1038/nature14397

    Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

    A resource for cell line authentication, annotation and quality control.

    Nature 520:307-311(2015)

     

    PubMed=26216984; DOI=10.1073/pnas.1501605112; PMCID=PMC4538616

    Daemen A., Peterson D., Sahu N., McCord R., Du X.-N., Liu B., Kowanetz K., Hong R., Moffat J., Gao M., Boudreau A., Mroue R., Corson L., O'Brien T., Qing J., Sampath D., Merchant M., Yauch R.L., Manning G., Settleman J., Hatzivassiliou G., Evangelista M.

    Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors.

    Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015)

     

    PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

    Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

    TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

    Genome Med. 7:118.1-118.7(2015)


     

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    该产品被引用文献

    *发表【中文论文】请标注:由博辉生物科技(广州)有限公司提供; *发表【英文论文】请标注:From Bohui Biological Technology (Guangzhou) Co., Ltd.

    相关实验
    • 04-流式细胞术上样盲点分析

      流式细胞术上样盲点

    • F值表(方差齐性检验用)

      3.82 3.47 3.25 3.09 2.97 2.87 2.80 2.73 2.64 2.53 2.42 2.31 2.18 2.04 21 22 4.38 3.73 3.44 3.21 3.05 2.93 2.84 2.76 2.70 2.60 2.50 2.39 2.27 2.14 2.00 22 23 4.35 3.75 3.41 3.18 3.02 2.90 2.81 2.73 2.67 2.57 2.47 2.36 2.24 2.11 1.97 23 24

    • v468 chapter 5 糖原合成酶激酶-3 的抑制

      . Fig. 5.1. Inhibition of GSK-3 activity. A Depletion of both GSK-3α and GSK-3β is required for a decrease of β-catenin phosphorylationat Ser33/37. Panc04.03 cells were transfected with shControl, shGSK-3α, and shGSK-3β vectors, as describedin

    图标技术资料

    资料下载:

    PANC05.04(BH-C165).docx 附 (下载 0 次)

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    询价
    上海沪震实业有限公司
    2026年04月27日询价
    ¥900
    上海泽叶生物科技有限公司
    2026年04月14日询价
    ¥1450
    上海富雨生物科技有限公司
    2026年01月13日询价
    询价
    蒂科(上海)生物科技有限公司
    2025年05月24日询价
    ¥900
    上海淳麦生物科技有限公司
    2025年07月15日询价
    文献支持
    PANC05.04细胞
    ¥1320